1. Home
  2. AIIR vs EVO Comparison

AIIR vs EVO Comparison

Compare AIIR & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIIR

Air Global PLC Ordinary Shares

N/A

Current Price

$7.22

Market Cap

1.1B

ML Signal

N/A

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$1.91

Market Cap

778.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIIR
EVO
Founded
N/A
1993
Country
United Arab Emirates
Germany
Employees
N/A
N/A
Industry
Tobacco
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
778.3M
IPO Year
2025
2007

Fundamental Metrics

Financial Performance
Metric
AIIR
EVO
Price
$7.22
$1.91
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
8.5K
46.8K
Earning Date
N/A
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.37
Revenue Next Year
N/A
$10.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.29
$1.89
52 Week High
$8.64
$4.27

Technical Indicators

Market Signals
Indicator
AIIR
EVO
Relative Strength Index (RSI) 53.88 37.04
Support Level $6.50 N/A
Resistance Level $7.38 $2.20
Average True Range (ATR) 0.68 0.05
MACD 0.07 0.01
Stochastic Oscillator 50.18 0.00

Price Performance

Historical Comparison
AIIR
EVO

About AIIR Air Global PLC Ordinary Shares

AIR Global PLC operates in the social inhalation products sector and has operations across multiple international markets. Its portfolio includes businesses and products related to shisha and hookah, including flavored shisha molasses, hookah and shisha e-commerce platforms, and charcoal-free shisha devices. The company also conducts product research and testing in partnership with independent laboratories to support the development of inhalation-related products and technologies.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: